Quantum Leap Advancements in In-Silico Drug Design (QIDD)

Dear Colleagues,

The rapidly evolving landscape of in silico drug design has witnessed unprecedented advancements that are transforming the approach to drug discovery and development. The Special Issue titled “Quantum Leap Advancements in In-Silico Drug Design (QIDD)” aims to showcase cutting-edge research and technological innovations that represent significant leaps forward in the field. One of the foremost advancements in this arena is the integration of artificial intelligence (AI) techniques. Machine learning and AI have become indispensable tools for predicting molecular properties and drug–target interactions. These technologies enhance the accuracy and efficiency of identifying potential therapeutic candidates by analyzing vast datasets to uncover patterns and relationships that traditional methods might lack. Specifically, the use of generative models, such as variational autoencoders (VAEs) and generative adversarial networks (GANs), has revolutionized the design of novel drug-like molecules. These models can generate new compounds with desired properties, significantly accelerating the drug discovery process. Moreover, quantum computing enables the precise prediction of binding affinities, novel molecule design, and detailed analyses of drug reactions by optimizing electronic structures and interactions with biological targets.

Multi-target docking is another critical development in QIDD that this Special Issue will explore. Traditional drug discovery often focuses on single-target interactions, but multi-target docking allows researchers to identify compounds that can interact with multiple targets simultaneously. This approach not only enhances therapeutic efficacy but also reduces the likelihood of side effects by targeting various pathways involved in different therapeutic interventions. Understanding the metabolic pathways influenced by potential drugs is essential for developing effective and safe medications. The utilization of metabolomics data in QIDD provides valuable insights into these pathways, aiding in the identification of biomarkers and the optimization of drug candidates. This holistic understanding of drug metabolism and its impact on the body can lead to more precise and personalized treatments. Incorporating diverse chemical databases into QIDD is another innovative approach highlighted in this Special Issue. By expanding virtual libraries to include a wide range of bioactive molecules from both synthetic chemicals and natural products, researchers can increase the chances of discovering novel therapeutic interventions. Natural products offer a rich source of unique compounds with potential therapeutic benefits. The scalability of virtual screening has been significantly enhanced using cloud computing platforms, which allow researchers to perform large-scale virtual screenings efficiently. High-performance computing (HPC) further complements this by providing the computational power needed to handle and analyze large datasets swiftly, making it feasible to conduct comprehensive virtual screenings and prioritize the most viable compounds for further development.

This Special Issue will unite leading researchers and practitioners to discuss these innovative approaches and their impact on pharmaceutical discovery and development. It will showcase the latest applications of QIDD, providing a comprehensive overview of current trends, challenges, and future directions. The integration of artificial intelligence, machine learning, multi-omics, diverse chemical libraries, cloud computing, and high-performance computing represents a convergence of technologies poised to revolutionize drug discovery. This Special Issue aims to highlight these transformative technologies and foster collaboration and innovation among researchers dedicated to QIDD.

Prof. Dr. Gilles Peslherbe
Dr. Satyavani Kaliamurthi
Dr. Gurudeeban Selvaraj
Prof. Dr. Dongqing Wei
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.